• 117: Migraine Explained: Triggers, Treatment, and When to Worry for Patients
    Jun 15 2026

    We break down migraines as a neurologic condition with a real brain-based chain reaction, not a character flaw or a one-off “bad headache.” We share practical prevention habits, how to track triggers, and how acute and preventive migraine medications fit together so you can walk into your next visit prepared.

    • what makes a migraine different from other headache types
    • common and less common migraine presentations including aura and scary look-alikes
    • the five-step migraine chain reaction including CGRP and pain amplification
    • high-yield triggers like stress, sleep changes, skipped meals, hormones, smells, and weather shifts
    • consistency as the core prevention theme across sleep, exercise, eating, and stress
    • migraine diary basics to identify patterns and improve your neurologist visit
    • when headaches warrant a call to a clinician and what red flags to take seriously
    • acute treatment options including OTC meds, triptans, CGRP blockers, and anti-nausea meds
    • medication overuse headache risk when acute meds are used too often
    • preventive options including beta blockers, anti-seizure meds, antidepressants, and Botox

    You can find us on Threads, you could send us an email, or you can send us some fan mail. We still have that voice-based fan mail still waiting for that first fateful one.


    Send us a (voice ) message with this link, we would love to hear from you. Standard message rates may apply.

    Support the show

    Production and Content: Edward Delesky, MD, DABOM & Nicole Aruffo, RN

    Artwork Rebrand and Avatars:

    Vantage Design Works (Vanessa Jones)

    Website: https://www.vantagedesignworks.com/

    Instagram: https://www.instagram.com/vantagedesignworks?igsh=aHRuOW93dmxuOG9m&utm_source=qr


    Original Artwork Concept: Olivia Pawlowski

    Mostra di più Mostra meno
    53 min
  • 116: Can Weight Loss Medications (GLP1s) Reduce Breast Cancer Risk?
    Jun 8 2026
    A headline like “weight loss drugs may reduce breast cancer risk” grabs attention fast, but the real story lives in the fine print. We take you through a new Penn Medicine study that observed lower breast cancer rates among women with overweight or obesity who used GLP-1 medications, then we translate what that finding actually means in plain language. Observational data can reveal a signal worth studying, but it cannot prove the medication caused the outcome, and that distinction matters for your decisions and your expectations. We also zoom out to the bigger why: obesity is not just about body size. Fat tissue is biologically active, shaping chronic inflammation, estrogen exposure after menopause, insulin resistance, and even how well the immune system spots abnormal cells. Those pathways help explain why obesity is linked to many cancers, including postmenopausal breast cancer, and why researchers are curious whether effective obesity treatment could shift risk over time. Then we get practical. We review what stronger evidence from randomized controlled trials says so far: GLP-1 drugs like Ozempic, Wegovy, Mounjaro, and Zepbound do not appear to increase breast cancer risk in the available trial data, even though most trials were not designed to study cancer outcomes for many years. We also discuss why newer studies seem most suggestive for hormone receptor positive breast cancer, along with the leading theories: weight loss itself, improved metabolic health and insulin signaling, reduced inflammation, and the still-unclear possibility of direct GLP-1 effects in cancer biology. If you like evidence-based medicine with real-world context (and a little Philly-life banter), subscribe, share this episode with a friend, and leave a review so more people can find the show. What question do you want answered next about GLP-1s, obesity treatment, or cancer risk?ReferencesRisk for Cancer With Glucagon-Like Peptide-1 Receptor Agonists and Dual Agonists : A Systematic Review and Meta-Analysis. Ko A, Chang YC, Bahar F, et al. Annals of Internal Medicine. 2025;. doi:10.7326/ANNALS-25-02237.Do GLP-1 Receptor Agonists Increase the Risk of Breast Cancer? A Systematic Review and Meta-Analysis. Piccoli GF, Mesquita LA, Stein C, et al. The Journal of Clinical Endocrinology and Metabolism. 2021;106(3):912-921. doi:10.1210/clinem/dgaa891.Glucagon-Like Peptide 1 Receptor Agonists and Cancer Risk: The Good, the Bad and the Unknown. Mannucci E, Dicembrini I. Nature Reviews. Clinical Oncology. 2026;23(6):459-470. doi:10.1038/s41571-026-01135-0.GLP-1 Agonists Are Associated With a Significant Reduction in Breast Cancer Incidence in Women. McDonald ES, Gillis LB, Gabriel P, et al. JCO Oncology Practice. 2026;:101200OP2600485. doi:10.1200/OP-26-00485.GLP-1 therapy and hormone receptor–positive breast cancer risk and survival: A real-world analysis.. Shah Z, Hundal J, Afridi S, et al. Journal of Clinical Oncology. 2026;44(Suppl 16):10548. doi:10.1200/JCO.2026.44.16_suppl.10548.Survival and Recurrence With GLP-1 Receptor Agonists in Breast Cancer. Tatum KL, Dahman B, Stevenson A, et al. JAMA Network Open. 2026;9(5):e2612133. doi:10.1001/jamanetworkopen.2026.12133.Association of Glucagon-Like Peptide-1 Receptor Agonists With Risk of Cancers-Evidence From a Drug Target Mendelian Randomization and Clinical Trials. Sun Y, Liu Y, Dian Y, et al. International Journal of Surgery (London, England). 2024;110(8):4688-4694. doi:10.1097/JS9.0000000000001514.GLP-1 receptor agonists and breast cancer risk in type 2 diabetes.. Guo Cheng and Amanda Ward. Journal of Clinical Oncology. 2025;43(Suppl 16):10557. doi:10.1200/JCO.2025.43.16_suppl.10557.Glucagon-Like Peptide-1 Analogues and Risk of Breast Cancer in Women With Type 2 Diabetes: Population Based Cohort Study Using the UK Clinical Practice Research Datalink. Hicks BM, Yin H, Yu OH, et al. BMJ (Clinical Research Ed.). 2016;355:i5340. doi:10.1136/bmj.i5340.GLP-1 Receptor Agonists and Cancer: Current Clinical Evidence and Translational Opportunities for Preclinical Research. Valencia-Rincón E, Rai R, Chandra V, Wellberg EA. The Journal of Clinical Investigation. 2025;135(21):e194743. doi:10.1172/JCI194743.Send us a (voice ) message with this link, we would love to hear from you. Standard message rates may apply.Support the showProduction and Content: Edward Delesky, MD, DABOM & Nicole Aruffo, RNArtwork Rebrand and Avatars:Vantage Design Works (Vanessa Jones) Website: https://www.vantagedesignworks.com/Instagram: https://www.instagram.com/vantagedesignworks?igsh=aHRuOW93dmxuOG9m&utm_source=qrOriginal Artwork Concept: Olivia Pawlowski
    Mostra di più Mostra meno
    26 min
  • 115: Are Food Preservatives Raising Your Blood Pressure? A New Study Explained
    Jun 1 2026

    That scary nutrition headline about preservatives and high blood pressure is everywhere right now and it’s easy to jump straight from “linked” to “proven.” We slow it down and do what we’d do in an exam room: look at what the study actually says, what it doesn’t say, and how to translate it into real-life choices that protect your heart without turning grocery shopping into a panic spiral.

    We talk through a new European Heart Journal paper using data from the NutriNet-Santé cohort (over 112,000 adults followed for nearly eight years) that finds several common food preservatives are associated with a higher risk of developing hypertension and cardiovascular disease. We explain why that word “associated” matters, how observational nutrition research can be confounded by overall ultra-processed food intake, sodium, fiber, lifestyle, and other factors, and why the results are best viewed as a signal not a verdict.

    Then we get practical by walking through a typical kitchen day and pointing out where you might run into additives like sodium nitrite, potassium sorbate, phosphoric acid, citric acid, and calcium propionate: breads, deli meats, chips, frozen meals, and even cola beverages. We also share the habits with the strongest evidence for blood pressure control: more minimally processed foods, more fruits and vegetables, less excess sodium, regular activity, better sleep, and stress management.

    If you found this helpful, subscribe, share it with a friend or neighbor, and leave a review so more people can find clear, patient-centered health info. What’s the first preservative you spot when you check five labels in your kitchen?

    Send us a (voice ) message with this link, we would love to hear from you. Standard message rates may apply.

    Support the show

    Production and Content: Edward Delesky, MD, DABOM & Nicole Aruffo, RN

    Artwork Rebrand and Avatars:

    Vantage Design Works (Vanessa Jones)

    Website: https://www.vantagedesignworks.com/

    Instagram: https://www.instagram.com/vantagedesignworks?igsh=aHRuOW93dmxuOG9m&utm_source=qr


    Original Artwork Concept: Olivia Pawlowski

    Mostra di più Mostra meno
    27 min
  • 114: COPD Explained Clearly for Patients
    May 25 2026

    Breathing out shouldn’t feel like pushing air through a straw, but for millions of people that’s the daily reality of COPD. We sit down and translate chronic obstructive pulmonary disease into plain English, starting with what the name really means and why the main problem is often getting air out, not just getting air in. If you’ve ever heard someone say they “can’t catch their breath,” we give you a clear picture of what may be happening inside the lungs.

    We walk through a simple model of breathing using an upside-down tree and tiny balloon-like air sacs, then explain what changes in COPD: inflamed, narrowed airways and air sacs that lose their stretch. That combination can trap air, making each new breath feel harder than the last. We also talk about the slow burn of how COPD develops over time, why smoking is the most common cause, and how pollution, occupational dust or chemicals, secondhand smoke, and rare genetic factors can also play a role.

    From there, we get practical. We cover common COPD symptoms (shortness of breath with activity, chronic cough, mucus, wheezing, fatigue), how spirometry helps diagnose airflow limitation, and what treatment can actually do. We discuss inhalers, pulmonary rehabilitation, oxygen therapy for advanced cases, and why staying up to date on flu, RSV, and COVID vaccines matters for people at higher risk. We also break down COPD exacerbations, the flare-ups often triggered by infections that can cause a step down in lung function, and why early prevention and timely care are so important.

    Stick around for our post-medicine banter too. If this helped you understand your body a little better, subscribe, share it with someone who needs it, and leave a review so more people can find straightforward health education.

    Send us a (voice ) message with this link, we would love to hear from you. Standard message rates may apply.

    Support the show

    Production and Content: Edward Delesky, MD, DABOM & Nicole Aruffo, RN

    Artwork Rebrand and Avatars:

    Vantage Design Works (Vanessa Jones)

    Website: https://www.vantagedesignworks.com/

    Instagram: https://www.instagram.com/vantagedesignworks?igsh=aHRuOW93dmxuOG9m&utm_source=qr


    Original Artwork Concept: Olivia Pawlowski

    Mostra di più Mostra meno
    20 min
  • 113: Health Trends Everywhere Right Now: Hype vs Reality
    May 18 2026

    Cortisol is getting blamed for basically everything online, and we get why it’s tempting: it gives a neat explanation for feeling tired, stressed, bloated, or “off.” But as a family medicine doctor and a nurse, we want to bring the conversation back to what cortisol actually does, what real testing looks like, and why most people don’t need to treat normal life stress like a hormonal crisis.

    From there, we zoom out to other trendy health topics we keep seeing everywhere: gut health and the microbiome, pricey supplement stacks, and the promise that one test will finally explain your symptoms. We talk about the evidence and the limits, plus the unglamorous basics that move the needle for most people: fiber, plants, sleep, exercise, and cutting back on ultra-processed foods.

    We also dig into CGMs and “glucose spikes,” including what’s normal (yes, exercise can raise glucose) and what actually signals risk, like blood sugar staying elevated after meals. Then we hit high-protein culture, why protein helps, why more isn’t always better, and how longevity trends can distract from what matters most. Our bottom line: wellness marketing moves faster than science, so we aim for practical, evidence-based choices you can stick with.

    If you found this helpful, subscribe, share it with a friend who’s stuck in health-trend overwhelm, and leave a review so more people can find the show.

    Send us a (voice ) message with this link, we would love to hear from you. Standard message rates may apply.

    Support the show

    Production and Content: Edward Delesky, MD, DABOM & Nicole Aruffo, RN

    Artwork Rebrand and Avatars:

    Vantage Design Works (Vanessa Jones)

    Website: https://www.vantagedesignworks.com/

    Instagram: https://www.instagram.com/vantagedesignworks?igsh=aHRuOW93dmxuOG9m&utm_source=qr


    Original Artwork Concept: Olivia Pawlowski

    Mostra di più Mostra meno
    42 min
  • 112: Hantavirus Explained: Why Experts Are Watching This Rare Virus
    May 11 2026

    “Rare, deadly virus” is a phrase that can hijack your nervous system, especially after the last few years. We slow the whole story down and walk through what hantavirus is, why it’s trending again, and how to tell the difference between a serious public health investigation and a true pandemic threat.

    We start with the headline that pulled hantavirus back into the spotlight: an unusual outbreak tied to a cruise ship traveling through parts of South America, with multiple passengers becoming seriously ill and reported deaths. From there, we explain why experts are paying close attention to the Andes virus strain, the one hantavirus with evidence of possible person-to-person spread, and what that actually means in real life. The key nuance: even when human transmission happens, it appears to require close, prolonged contact, not the kind of casual exposure that drives rapid global spread.

    Then we zoom into the practical, everyday risks that matter most for listeners. Hantavirus pulmonary syndrome (HPS) can begin with flu-like symptoms such as fever, fatigue, muscle aches, headaches, and nausea, and in some cases it can progress quickly to severe lung problems. We cover the most common route of infection: rodent exposure, especially when cleaning dusty enclosed spaces like sheds, cabins, garages, barns, and attics. You’ll leave with clear prevention steps inspired by public health guidance, like ventilating first, using disinfectant, wearing gloves, and avoiding dry sweeping or vacuuming droppings.

    If you want facts, context, and a calmer way to process outbreak news, hit play, share this with someone who’s anxious about the headlines, and subscribe so you don’t miss the next checkup. If our show helps, leave a review and tell us what health topic you want us to unpack next.

    Send us a (voice ) message with this link, we would love to hear from you. Standard message rates may apply.

    Support the show

    Production and Content: Edward Delesky, MD, DABOM & Nicole Aruffo, RN

    Artwork Rebrand and Avatars:

    Vantage Design Works (Vanessa Jones)

    Website: https://www.vantagedesignworks.com/

    Instagram: https://www.instagram.com/vantagedesignworks?igsh=aHRuOW93dmxuOG9m&utm_source=qr


    Original Artwork Concept: Olivia Pawlowski

    Mostra di più Mostra meno
    24 min
  • 111: What To Expect When You Begin a GLP-1
    May 4 2026

    GLP-1 medications can feel like a Rorschach test online: one person calls Ozempic or Wegovy a miracle, another calls it miserable, and almost nobody explains what the “normal middle” looks like. We wanted to fix that with a practical walkthrough of what tends to happen after you start a GLP-1 receptor agonist, especially in those first weeks when you’re on a low dose and you’re wondering if anything is happening at all.

    We talk through the early ramp-up, realistic weight loss expectations, and the biggest lived experience change we hear from patients: food noise getting quieter. We break down the difference between normal hunger cues and constant appetite chatter, why cravings often drop, and how that creates a real window of opportunity to build routines that used to be hard. We also get honest about common side effects like nausea, constipation, and feeling overly full, plus simple strategies that can make them more manageable and safer.

    Then we zoom out to the long game: what it means to treat obesity as a chronic condition, why plateaus don’t automatically mean the medication “stopped working,” and how to define success beyond a single scale number using cardiometabolic health wins. After the clinical talk, we lighten things up with some banter about Ollie’s pet store obsession and the strange things strangers say on a walk.

    If this helped you, subscribe, share it with a loved one, and leave a review so more people can find practical, judgment-free education on GLP-1s and healthy weight loss.

    Send us a (voice ) message with this link, we would love to hear from you. Standard message rates may apply.

    Support the show

    Production and Content: Edward Delesky, MD, DABOM & Nicole Aruffo, RN

    Artwork Rebrand and Avatars:

    Vantage Design Works (Vanessa Jones)

    Website: https://www.vantagedesignworks.com/

    Instagram: https://www.instagram.com/vantagedesignworks?igsh=aHRuOW93dmxuOG9m&utm_source=qr


    Original Artwork Concept: Olivia Pawlowski

    Mostra di più Mostra meno
    32 min
  • 110: When To Consider Starting a GLP-1 (Wegovy, Zepbound): Honest Guide for Patients
    Apr 27 2026

    A medication that can support weight loss, lower diabetes risk, and protect your heart sounds almost too good to be true. So we get practical about the real decision: not “Do I want a GLP-1?” but “What problem am I trying to solve?” If the goal is better metabolic health, less sleep apnea burden, improved blood pressure, or a long-term plan for obesity as a chronic disease, the conversation changes fast.

    We break down who should seriously consider GLP-1 medications like Ozempic, Wegovy, Zepbound, and Mounjaro, including the common BMI thresholds and the “BMI plus comorbidity” situations. We also talk about the people who have truly done the nutrition and exercise work, lost weight, and watched their body push back with hunger and regain. That’s where appetite dysregulation and biology matter, and where GLP-1s can become a powerful tool instead of a moral debate.

    We also cover who should pause before starting: anyone chasing a quick fix, anyone who hasn’t built foundational habits, or anyone who isn’t ready for the trade-offs like nausea, fatigue, or constipation. We dig into safety and long-term expectations, why stopping often brings symptoms back, and why easy access through med spas and low-oversight online clinics can be risky, especially with disordered eating history. If you want a calmer, more responsible way to decide, we’ll help you map the choice to your story.

    Subscribe for more practical health conversations, share this with a friend who’s on the fence, and leave a review if it helped. What’s the biggest question you still have about starting a GLP-1?

    Send us a (voice ) message with this link, we would love to hear from you. Standard message rates may apply.

    Support the show

    Production and Content: Edward Delesky, MD, DABOM & Nicole Aruffo, RN

    Artwork Rebrand and Avatars:

    Vantage Design Works (Vanessa Jones)

    Website: https://www.vantagedesignworks.com/

    Instagram: https://www.instagram.com/vantagedesignworks?igsh=aHRuOW93dmxuOG9m&utm_source=qr


    Original Artwork Concept: Olivia Pawlowski

    Mostra di più Mostra meno
    33 min